SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Eledon Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Business Highlights

Planned global Phase 3 LEGACY trial of tegoprubart in kidney transplantation remains on track to ini

ELDN

Related stories